Kaempferol Alleviates Hepatic Injury in Nonalcoholic Steatohepatitis (NASH) by Suppressing Neutrophil-Mediated NLRP3-ASC/TMS1-Caspase 3 Signaling
Molecules · 2024
DOI: 10.3390/molecules29112630 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2024. Verfasst von He Yang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Medical School, University of Chinese Academy of Sciences, Beijing 101408, China. Hauptthemen laut MEDLINE: Kaempferols, Non-alcoholic Fatty Liver Disease, NLR Family, Pyrin Domain-Containing 3 Protein, Signal Transduction. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Chinese Academy of Sciences.
Abstract (Originalsprache)
Background
Non-alcoholic fatty liver disease (NAFLD) is a significant hepatic condition that has gained worldwide attention. Kaempferol (Kae), renowned for its diverse biological activities, including anti-inflammatory, antioxidant, anti-aging, and cardio-protective properties, has emerged as a potential therapeutic candidate for non-alcoholic steatohepatitis (NASH). Despite its promising therapeutic potential, the precise underlying mechanism of Kae’s beneficial effects in NASH remains unclear. Therefore, this study aims to clarify the mechanism by conducting comprehensive in vivo and in vitro experiments.
Results
In this study, a murine model of non-alcoholic steatohepatitis (NASH) was established by feeding C57BL/6 female mice a high-fat diet for 12 weeks. Kaempferol (Kae) was investigated for its ability to modulate systemic inflammatory responses and lipid metabolism in this model (20 mg/kg per day). Notably, Kae significantly reduced the expression of NLRP3-ASC/TMS1-Caspase 3, a crucial mediator of liver tissue inflammation. Additionally, in a HepG2 cell model induced with palmitic acid/oleic acid (PA/OA) to mimic NASH conditions, Kae demonstrated the capacity to decrease lipid droplet accumulation and downregulate the expression of NLRP3-ASC/TMS1-Caspase 3 (20 µM and the final concentration to 20 nM). These findings suggest that Kae may hold therapeutic potential in the treatment of NASH by targeting inflammatory and metabolic pathways.
Conclusions
These findings suggest that kaempferol holds potential as a promising therapeutic intervention for ameliorating non-alcoholic fatty liver disease (NAFLD).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical School, University of Chinese Academy of Sciences, Beijing 101408, China.
Förderung
- University of Chinese Academy of Sciences
Zitieren
APA
Yang, H., Li, D., & Gao, G. (2024). Kaempferol Alleviates Hepatic Injury in Nonalcoholic Steatohepatitis (NASH) by Suppressing Neutrophil-Mediated NLRP3-ASC/TMS1-Caspase 3 Signaling. Molecules. https://doi.org/10.3390/molecules29112630
Vancouver
Yang H, Li D, Gao G. Kaempferol Alleviates Hepatic Injury in Nonalcoholic Steatohepatitis (NASH) by Suppressing Neutrophil-Mediated NLRP3-ASC/TMS1-Caspase 3 Signaling. Molecules. 2024. doi:10.3390/molecules29112630
BibTeX
@article{Yang2024,
author = {Yang, He and Li, Dandan and Gao, Guolan},
title = {Kaempferol Alleviates Hepatic Injury in Nonalcoholic Steatohepatitis (NASH) by Suppressing Neutrophil-Mediated NLRP3-ASC/TMS1-Caspase 3 Signaling},
journal = {Molecules},
year = {2024},
doi = {10.3390/molecules29112630}
}
EUVIMED